Prognostic value of microRNAs in head and neck cancers

A systematic review and meta-analysis protocol

Chellan Kumarasamy, Arikketh Devi, Rama Jayaraj

Research output: Contribution to journalReview articleResearchpeer-review

17 Downloads (Pure)

Abstract

Background: Head and neck cancers form a significant share of all cancer incidences worldwide. Though treatment modalities exist, post-treatment recurrence and survival rates in recurrent patients continue to be high. MiRNAs offer an effective method of estimating the probability of recurrence and survival of HNC patients, thereby allowing for effective treatment and better survival rates.

Methods: The systematic review protocol was prepared according to the Preferred Reporting Items for Systematic Review and Meta-Analyses Protocols (PRISMA-P) 2015 statement. Relevant studies will be identified by a rigorous search of multiple bibliographical databases, including MEDLINE, Scopus, PubMed, Web of Science, Embase and Science Direct, without any language restrictions (up to June 2018). The primary screening will be performed by a review team via analysis of titles and abstracts of published articles. Final selection of articles will be achieved by two independent reviewers, based on predefined selection criteria. Data will be extracted from eligible studies using a pre-piloted data extraction form. Statistical analysis will be performed on the basis of available data, extracted from eligible studies. Meta-analysis will be performed, and a forest plot will be generated, to determine pooled hazard ratios (HR) and 95% confidence interval (CI) using CMA. A fixed or random-effects model of meta-analysis will be used depending upon the between-study heterogeneity; publication bias will be determined by the Egger’s bias indicator test. A narrative synthesis will be undertaken where statistical data is found to be insufficient.

Discussion: There is a lack of highly sensitive and specific biomarkers for estimating the HNC patients’ prognostic outcomes, particularly in post-treatment conditions. This systematic review will identify and validate specific miRNA as prognostic biomarkers by utilising a collection of previously published data on miRNA expression and survival. Highlighting these prognostic specific miRNAs will have major clinical implications by allowing for better overall treatment strategies and patient survival estimates, by offering clinicians a method of quantitatively analysing prognosis via miRNA expression.
Original languageEnglish
Article number150
Pages (from-to)1-6
Number of pages6
JournalSystematic Reviews
Volume7
Issue number1
DOIs
Publication statusPublished - 2 Oct 2018

Fingerprint

Head and Neck Neoplasms
MicroRNAs
Meta-Analysis
Survival
Survival Rate
Biomarkers
Therapeutics
Recurrence
Publication Bias
PubMed
MEDLINE
Patient Selection
Language
Databases
Confidence Intervals
Incidence
Neoplasms

Cite this

Kumarasamy, Chellan ; Devi, Arikketh ; Jayaraj, Rama. / Prognostic value of microRNAs in head and neck cancers : A systematic review and meta-analysis protocol. In: Systematic Reviews. 2018 ; Vol. 7, No. 1. pp. 1-6.
@article{2dece64fa9a04c6a92200a113ed4f3f8,
title = "Prognostic value of microRNAs in head and neck cancers: A systematic review and meta-analysis protocol",
abstract = "Background: Head and neck cancers form a significant share of all cancer incidences worldwide. Though treatment modalities exist, post-treatment recurrence and survival rates in recurrent patients continue to be high. MiRNAs offer an effective method of estimating the probability of recurrence and survival of HNC patients, thereby allowing for effective treatment and better survival rates.Methods: The systematic review protocol was prepared according to the Preferred Reporting Items for Systematic Review and Meta-Analyses Protocols (PRISMA-P) 2015 statement. Relevant studies will be identified by a rigorous search of multiple bibliographical databases, including MEDLINE, Scopus, PubMed, Web of Science, Embase and Science Direct, without any language restrictions (up to June 2018). The primary screening will be performed by a review team via analysis of titles and abstracts of published articles. Final selection of articles will be achieved by two independent reviewers, based on predefined selection criteria. Data will be extracted from eligible studies using a pre-piloted data extraction form. Statistical analysis will be performed on the basis of available data, extracted from eligible studies. Meta-analysis will be performed, and a forest plot will be generated, to determine pooled hazard ratios (HR) and 95{\%} confidence interval (CI) using CMA. A fixed or random-effects model of meta-analysis will be used depending upon the between-study heterogeneity; publication bias will be determined by the Egger’s bias indicator test. A narrative synthesis will be undertaken where statistical data is found to be insufficient.Discussion: There is a lack of highly sensitive and specific biomarkers for estimating the HNC patients’ prognostic outcomes, particularly in post-treatment conditions. This systematic review will identify and validate specific miRNA as prognostic biomarkers by utilising a collection of previously published data on miRNA expression and survival. Highlighting these prognostic specific miRNAs will have major clinical implications by allowing for better overall treatment strategies and patient survival estimates, by offering clinicians a method of quantitatively analysing prognosis via miRNA expression.",
keywords = "Head and neck cancer (HNC), Meta-analysis, miRNA, PRISMA, Prognosis, Protocol, Survival, Systematic review",
author = "Chellan Kumarasamy and Arikketh Devi and Rama Jayaraj",
year = "2018",
month = "10",
day = "2",
doi = "10.1186/s13643-018-0812-8",
language = "English",
volume = "7",
pages = "1--6",
journal = "Systematic Reviews",
issn = "2046-4053",
publisher = "BioMed Central",
number = "1",

}

Prognostic value of microRNAs in head and neck cancers : A systematic review and meta-analysis protocol. / Kumarasamy, Chellan; Devi, Arikketh; Jayaraj, Rama.

In: Systematic Reviews, Vol. 7, No. 1, 150, 02.10.2018, p. 1-6.

Research output: Contribution to journalReview articleResearchpeer-review

TY - JOUR

T1 - Prognostic value of microRNAs in head and neck cancers

T2 - A systematic review and meta-analysis protocol

AU - Kumarasamy, Chellan

AU - Devi, Arikketh

AU - Jayaraj, Rama

PY - 2018/10/2

Y1 - 2018/10/2

N2 - Background: Head and neck cancers form a significant share of all cancer incidences worldwide. Though treatment modalities exist, post-treatment recurrence and survival rates in recurrent patients continue to be high. MiRNAs offer an effective method of estimating the probability of recurrence and survival of HNC patients, thereby allowing for effective treatment and better survival rates.Methods: The systematic review protocol was prepared according to the Preferred Reporting Items for Systematic Review and Meta-Analyses Protocols (PRISMA-P) 2015 statement. Relevant studies will be identified by a rigorous search of multiple bibliographical databases, including MEDLINE, Scopus, PubMed, Web of Science, Embase and Science Direct, without any language restrictions (up to June 2018). The primary screening will be performed by a review team via analysis of titles and abstracts of published articles. Final selection of articles will be achieved by two independent reviewers, based on predefined selection criteria. Data will be extracted from eligible studies using a pre-piloted data extraction form. Statistical analysis will be performed on the basis of available data, extracted from eligible studies. Meta-analysis will be performed, and a forest plot will be generated, to determine pooled hazard ratios (HR) and 95% confidence interval (CI) using CMA. A fixed or random-effects model of meta-analysis will be used depending upon the between-study heterogeneity; publication bias will be determined by the Egger’s bias indicator test. A narrative synthesis will be undertaken where statistical data is found to be insufficient.Discussion: There is a lack of highly sensitive and specific biomarkers for estimating the HNC patients’ prognostic outcomes, particularly in post-treatment conditions. This systematic review will identify and validate specific miRNA as prognostic biomarkers by utilising a collection of previously published data on miRNA expression and survival. Highlighting these prognostic specific miRNAs will have major clinical implications by allowing for better overall treatment strategies and patient survival estimates, by offering clinicians a method of quantitatively analysing prognosis via miRNA expression.

AB - Background: Head and neck cancers form a significant share of all cancer incidences worldwide. Though treatment modalities exist, post-treatment recurrence and survival rates in recurrent patients continue to be high. MiRNAs offer an effective method of estimating the probability of recurrence and survival of HNC patients, thereby allowing for effective treatment and better survival rates.Methods: The systematic review protocol was prepared according to the Preferred Reporting Items for Systematic Review and Meta-Analyses Protocols (PRISMA-P) 2015 statement. Relevant studies will be identified by a rigorous search of multiple bibliographical databases, including MEDLINE, Scopus, PubMed, Web of Science, Embase and Science Direct, without any language restrictions (up to June 2018). The primary screening will be performed by a review team via analysis of titles and abstracts of published articles. Final selection of articles will be achieved by two independent reviewers, based on predefined selection criteria. Data will be extracted from eligible studies using a pre-piloted data extraction form. Statistical analysis will be performed on the basis of available data, extracted from eligible studies. Meta-analysis will be performed, and a forest plot will be generated, to determine pooled hazard ratios (HR) and 95% confidence interval (CI) using CMA. A fixed or random-effects model of meta-analysis will be used depending upon the between-study heterogeneity; publication bias will be determined by the Egger’s bias indicator test. A narrative synthesis will be undertaken where statistical data is found to be insufficient.Discussion: There is a lack of highly sensitive and specific biomarkers for estimating the HNC patients’ prognostic outcomes, particularly in post-treatment conditions. This systematic review will identify and validate specific miRNA as prognostic biomarkers by utilising a collection of previously published data on miRNA expression and survival. Highlighting these prognostic specific miRNAs will have major clinical implications by allowing for better overall treatment strategies and patient survival estimates, by offering clinicians a method of quantitatively analysing prognosis via miRNA expression.

KW - Head and neck cancer (HNC)

KW - Meta-analysis

KW - miRNA

KW - PRISMA

KW - Prognosis

KW - Protocol

KW - Survival

KW - Systematic review

UR - http://www.scopus.com/inward/record.url?scp=85054330738&partnerID=8YFLogxK

U2 - 10.1186/s13643-018-0812-8

DO - 10.1186/s13643-018-0812-8

M3 - Review article

VL - 7

SP - 1

EP - 6

JO - Systematic Reviews

JF - Systematic Reviews

SN - 2046-4053

IS - 1

M1 - 150

ER -